Wealth Enhancement Advisory Services
MRSN

Wealth Enhancement Advisory Services’s Mersana Therapeutics MRSN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,069
Closed -$36.7K – 3654
2025
Q2 		$36.7K Sell
5,069
-159
-3% -$1.4K ﹤0.01% 3254
2025
Q1 		$45K Buy
+5,228
New +$80.7K ﹤0.01% 2859

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wealth Enhancement Advisory Services's MRSN Position: Q3 2025 in Review

Wealth Enhancement Advisory Services sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 5,069 shares — an estimated $36.7K sold.

Wealth Enhancement Advisory Services first reported a position in MRSN in Q1 2025 and held it in 2 quarters. The position peaked at $45K in Q1 2025. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Wealth Enhancement Advisory Services reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 5,069 Mersana Therapeutics shares in Q3 2025, an estimated $36.7K.
  • Wealth Enhancement Advisory Services first reported a position in Mersana Therapeutics in Q1 2025 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's Mersana Therapeutics position peaked at $45K in Q1 2025.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2025, filed 29 Oct 2025.